Abstract
Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.
In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.
Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.
Current Cancer Therapy Reviews
Title:Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Volume: 9 Issue: 1
Author(s): Alessandra Romano, Giuseppina Uccello, Paolo Spina, Rosario Cunsolo, Calogero Vetro and Francesco Di Raimondo
Affiliation:
Keywords: Multiple myeloma, relapse, doxorubicin, salvage chemotherapy.
Abstract: Anthracyclines show anti myeloma effects, being part of active regimens like infusional vincristine/ doxorubicin/ pulsed dexamethasone (VAD) in the past and recently of bortezomib/doxorubicin/pulsed dexamethasone (PAD) for the treatment of multiple myeloma. The recent introduction of pegylated liposomal doxorubicin has led to the development of newer anthracycline-containing regimens with improved toxicity profiles.
In vitro, anthracyclines are able of suppressing bortezomib-mediated induction of some stress response proteins with a large synergic effect. Clinical trials have shown impressive activity of pegylated liposomal doxorubicin and conventional doxorubicin in combination with bortezomib in patients with relapsed/refractory myeloma. Herein, we review the clinical data supporting the use of pegylated liposomal doxorubicin combined to active agents in salvage regimens for relapsed/ refractory multiple myeloma patients.
Export Options
About this article
Cite this article as:
Romano Alessandra, Uccello Giuseppina, Spina Paolo, Cunsolo Rosario, Vetro Calogero and Raimondo Di Francesco, Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010001
DOI https://dx.doi.org/10.2174/1573394711309010001 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Multiple Drug Resistance Associated with Function of ABC-Transporters in Diabetes Mellitus: Molecular Mechanism and Clinical Relevance
Infectious Disorders - Drug Targets Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Altered Prolylcarboxypeptidase Expression and Function in Response to Different Risk Factors of Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Current Drug Targets Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment
Current Stem Cell Research & Therapy MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress
Current Neurovascular Research Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Derivatives of Resveratrol: Potential Agents in Prevention and Treatment of Cardiovascular Disease
Current Medicinal Chemistry Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews